<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956550</url>
  </required_header>
  <id_info>
    <org_study_id>R5069-OA-1849</org_study_id>
    <nct_id>NCT03956550</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the efficacy of REGN5069 compared to&#xD;
      placebo in patients with pain due to radiographically-confirmed OA of the knee who have a&#xD;
      history of inadequate joint pain relief or intolerance to current analgesic therapy.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To characterize the concentrations of functional REGN5069 in serum over time when&#xD;
           patients are treated for up to 12 weeks&#xD;
&#xD;
        -  To assess the safety and tolerability of REGN5069 compared with placebo when patients&#xD;
           are treated for up to 12 weeks&#xD;
&#xD;
        -  To measure levels of anti-drug antibodies (ADAs) against REGN5069 following multiple IV&#xD;
           administrations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3,&#xD;
    which was previously being studied in osteoarthritis pain of the knee&#xD;
  </why_stopped>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Actual">October 29, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in WOMAC Total Score</measure>
    <time_frame>Week 12</time_frame>
    <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in WOMAC Physical Function Subscale Score</measure>
    <time_frame>Week 12</time_frame>
    <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Patient Global Assessment (PGA) Score</measure>
    <time_frame>Week 12</time_frame>
    <description>The Patient Global Assessment of OA (PGA) is a patient-rated assessment of current disease state on a 5-point Likert scale (1 = very good; 2 = good; 3 = fair; 4 = poor; and 5 = very poor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in WOMAC Stiffness Subscale Score</measure>
    <time_frame>Week 12</time_frame>
    <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥30% Improvement in WOMAC Pain Subscale Score</measure>
    <time_frame>Week 12</time_frame>
    <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Non-Serious and Serious Treatment-Emergent Adverse Events (TEAEs) Through End of Study</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient administered a study drug which may or may not have a causal relationship with the study drug. Treatment-emergent AEs (TEAEs) are AEs that developed or worsened during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Imaging Abnormalities Consistent With Adjudicated Arthropathies Through End of Study</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Adjudicated arthropathy is an umbrella term referring to Rapidly Progressive Osteoarthritis Type 1 (RPOA-1), Rapidly Progressive Osteoarthritis Type 2 (RPOA-2), subchondral insufficiency fractures (SIF) and osteonecrosis (ON) confirmed by an arthropathy adjudication committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Presence of Anti-REGN5049 Antibody Development Through End of Study</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Immunogenicity will be characterized by ADA responses &amp; titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses &lt; 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, ≥ 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the REG5069 ADA assay post first dose when baseline results = negative or missing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">259</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>REGN5069 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized in a 1:1:1 ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN5069 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized in a 1:1:1 ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized in a 1:1:1 ratio</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN5069</intervention_name>
    <description>Intravenous (IV) Dose every 4 weeks (Q4W)</description>
    <arm_group_label>REGN5069 High Dose</arm_group_label>
    <arm_group_label>REGN5069 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Intravenous (IV) Dose every 4 weeks (QW4)</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Generally in good health at the screening visit&#xD;
&#xD;
          -  Body mass index (BMI) ≤39 kg/m2 at the screening visit&#xD;
&#xD;
          -  Clinical diagnosis of OA of the knee on the American College of Rheumatology criteria&#xD;
             (Altman, 1986) with radiologic evidence of OA (K-L score ≥2) at the index joint at the&#xD;
             screening visit&#xD;
&#xD;
          -  Moderate-to-severe pain in the index joint&#xD;
&#xD;
          -  A history of inadequate pain relief from or intolerance to analgesics used for OA&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of systemic diseases that may affect joints&#xD;
&#xD;
          -  History or presence of osteonecrosis, destructive arthropathy, neuropathic joint&#xD;
             arthropathy, pathologic fractures in any shoulder, hip, or knee joint(s), hip&#xD;
             dislocation (prosthetic hip dislocation is eligible), or knee dislocation (patella&#xD;
             dislocation is eligible) at the screening visit. Presence of subchondral insufficiency&#xD;
             fracture on screening films or MRI as assessed by the central imaging reader.&#xD;
&#xD;
          -  Is scheduled for a joint replacement surgery to be performed during the study period&#xD;
&#xD;
          -  Received an intra-articular injection of hyaluronic acid in any joint within 90 days&#xD;
             prior to the screening visit&#xD;
&#xD;
          -  Systemic (ie, IV, oral, or intramuscular) corticosteroids within 30 days prior to the&#xD;
             screening visit. Intra-articular corticosteroids in the index joint within 12 weeks&#xD;
             prior to the screening visit, or to any other joint within 30 days prior to the&#xD;
             screening visit (topical, intranasal, or inhaled corticosteroids are permitted).&#xD;
&#xD;
          -  History or presence at the screening visit of multiple sclerosis, autonomic&#xD;
             neuropathy, diabetic neuropathy, or other peripheral neuropathy&#xD;
&#xD;
          -  Significant concomitant illness including, but not limited to, psychiatric, cardiac,&#xD;
             renal, hepatic, neurological, endocrinological, metabolic, or lymphatic disease that,&#xD;
             in the opinion of the investigator, would adversely affect the patient's participation&#xD;
             in the study&#xD;
&#xD;
          -  History of myocardial infarction, acute coronary syndromes, transient ischemic attack,&#xD;
             or cerebrovascular accident within 12 months prior to the screening visit&#xD;
&#xD;
        Note: Other protocol defined inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tbilisi</city>
        <zip>112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Zgierz</city>
        <state>Lodzkie</state>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-412</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Zamosc</city>
        <state>Lubelskie</state>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>02 - 777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Kyiv</city>
        <zip>1135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>June 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2021</results_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03956550/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03956550/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 5 countries and 12 sites participated in enrollment. It consisted of screening period up to 30 days, followed by a 12-week randomized, double-blind, placebo-controlled treatment period, a 24-week follow-up period, and end-of-study phone call approximately 52 weeks after first dose. Study was terminated after all participants completed the week 36 visits.</recruitment_details>
      <pre_assignment_details>A total of 259 participants were randomized in 1:1:1 ratio to receive REGN5069 at 100 mg IV Q4W, REGN5069 at 1000 mg IV Q4W, or matching placebo Q4W. Participants were to receive 3 fixed-dose IV infusions at baseline, week 4, and week 8. 171 participants were randomized to receive REGN5069 (86 participants in the 100 mg Q4W group and 85 in the 1000 mg Q4W group) and 88 were randomized to receive placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
        </group>
        <group group_id="P2">
          <title>REGN5069 100 mg Q4W</title>
          <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
        </group>
        <group group_id="P3">
          <title>REGN5069 1000 mg Q4W</title>
          <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
        </group>
        <group group_id="B2">
          <title>REGN5069 100 mg Q4W</title>
          <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
        </group>
        <group group_id="B3">
          <title>REGN5069 1000 mg Q4W</title>
          <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="259"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Full analysis set population (FAS): included all randomized participants</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="8.27"/>
                    <measurement group_id="B2" value="63.9" spread="7.39"/>
                    <measurement group_id="B3" value="64.7" spread="8.30"/>
                    <measurement group_id="B4" value="64.0" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Full analysis set population (FAS): included all randomized participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="206"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Full analysis set population (FAS): included all randomized participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Full analysis set population (FAS): included all randomized participants</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score</title>
          <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
          <population>Here 'n' = number of evaluable participants at this time interval</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="87"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="85"/>
                    <count group_id="B4" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.68" spread="1.257"/>
                    <measurement group_id="B2" value="6.24" spread="1.203"/>
                    <measurement group_id="B3" value="6.47" spread="1.150"/>
                    <measurement group_id="B4" value="6.36" spread="1.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</title>
        <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Full analysis set population (FAS): included all randomized participants; Here 'n' = number of evaluable participants at the specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</title>
          <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
          <population>Full analysis set population (FAS): included all randomized participants; Here 'n' = number of evaluable participants at the specific time point.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="0.188"/>
                    <measurement group_id="O2" value="-2.37" spread="0.191"/>
                    <measurement group_id="O3" value="-1.98" spread="0.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2978</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6890</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in WOMAC Total Score</title>
        <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set population (FAS): included all randomized participants; Here &quot;number analyzed&quot; = number of evaluable participants at this time interval</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in WOMAC Total Score</title>
          <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
          <population>Full analysis set population (FAS): included all randomized participants; Here &quot;number analyzed&quot; = number of evaluable participants at this time interval</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="0.177"/>
                    <measurement group_id="O2" value="-2.15" spread="0.179"/>
                    <measurement group_id="O3" value="-1.81" spread="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1973</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9420</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in WOMAC Physical Function Subscale Score</title>
        <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set population (FAS): included all randomized participants; Here 'n' = number of evaluable participants at the specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in WOMAC Physical Function Subscale Score</title>
          <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
          <population>Full analysis set population (FAS): included all randomized participants; Here 'n' = number of evaluable participants at the specific time point.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="0.180"/>
                    <measurement group_id="O2" value="-2.09" spread="0.183"/>
                    <measurement group_id="O3" value="-1.75" spread="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1597</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9719</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Patient Global Assessment (PGA) Score</title>
        <description>The Patient Global Assessment of OA (PGA) is a patient-rated assessment of current disease state on a 5-point Likert scale (1 = very good; 2 = good; 3 = fair; 4 = poor; and 5 = very poor).</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set population (FAS): included all randomized participants; Here 'n' = number of evaluable participants at the specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Patient Global Assessment (PGA) Score</title>
          <description>The Patient Global Assessment of OA (PGA) is a patient-rated assessment of current disease state on a 5-point Likert scale (1 = very good; 2 = good; 3 = fair; 4 = poor; and 5 = very poor).</description>
          <population>Full analysis set population (FAS): included all randomized participants; Here 'n' = number of evaluable participants at the specific time point.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.076"/>
                    <measurement group_id="O2" value="-0.75" spread="0.078"/>
                    <measurement group_id="O3" value="-0.80" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1365</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0604</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in WOMAC Stiffness Subscale Score</title>
        <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set population (FAS): included all randomized participants; Here 'n' = number of evaluable participants at the specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in WOMAC Stiffness Subscale Score</title>
          <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
          <population>Full analysis set population (FAS): included all randomized participants; Here 'n' = number of evaluable participants at the specific time point.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="0.214"/>
                    <measurement group_id="O2" value="-2.20" spread="0.217"/>
                    <measurement group_id="O3" value="-1.88" spread="0.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0989</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5487</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥30% Improvement in WOMAC Pain Subscale Score</title>
        <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set population (FAS): included all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥30% Improvement in WOMAC Pain Subscale Score</title>
          <description>The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.</description>
          <population>Full analysis set population (FAS): included all randomized participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1"/>
                    <measurement group_id="O2" value="58.1"/>
                    <measurement group_id="O3" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3572</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5747</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Non-Serious and Serious Treatment-Emergent Adverse Events (TEAEs) Through End of Study</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a patient administered a study drug which may or may not have a causal relationship with the study drug. Treatment-emergent AEs (TEAEs) are AEs that developed or worsened during the treatment period.</description>
        <time_frame>Baseline to Week 36</time_frame>
        <population>Safety Analysis Set (SAF): included all randomized participants who received any study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Non-Serious and Serious Treatment-Emergent Adverse Events (TEAEs) Through End of Study</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a patient administered a study drug which may or may not have a causal relationship with the study drug. Treatment-emergent AEs (TEAEs) are AEs that developed or worsened during the treatment period.</description>
          <population>Safety Analysis Set (SAF): included all randomized participants who received any study drug</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Imaging Abnormalities Consistent With Adjudicated Arthropathies Through End of Study</title>
        <description>Adjudicated arthropathy is an umbrella term referring to Rapidly Progressive Osteoarthritis Type 1 (RPOA-1), Rapidly Progressive Osteoarthritis Type 2 (RPOA-2), subchondral insufficiency fractures (SIF) and osteonecrosis (ON) confirmed by an arthropathy adjudication committee.</description>
        <time_frame>Baseline to Week 36</time_frame>
        <population>Safety Analysis Set (SAF): included all randomized participants who received any study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Imaging Abnormalities Consistent With Adjudicated Arthropathies Through End of Study</title>
          <description>Adjudicated arthropathy is an umbrella term referring to Rapidly Progressive Osteoarthritis Type 1 (RPOA-1), Rapidly Progressive Osteoarthritis Type 2 (RPOA-2), subchondral insufficiency fractures (SIF) and osteonecrosis (ON) confirmed by an arthropathy adjudication committee.</description>
          <population>Safety Analysis Set (SAF): included all randomized participants who received any study drug</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Up to and Including Week 12 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Week 12 Visit, Up to and Including Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Presence of Anti-REGN5049 Antibody Development Through End of Study</title>
        <description>Immunogenicity will be characterized by ADA responses &amp; titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses &lt; 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, ≥ 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the REG5069 ADA assay post first dose when baseline results = negative or missing.</description>
        <time_frame>Baseline to Week 36</time_frame>
        <population>Anti-Drug Antibody (ADA) Analysis Set: included all treated participants who received any amount of study drug (active or placebo [safety analysis set (SAF)]) and had at least one non-missing anti-REGN5069 antibody result following the first dose of study drug or placebo. ADA analysis set is based on actual treatment received, rather than randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O2">
            <title>REGN5069 100 mg Q4W</title>
            <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
          <group group_id="O3">
            <title>REGN5069 1000 mg Q4W</title>
            <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Presence of Anti-REGN5049 Antibody Development Through End of Study</title>
          <description>Immunogenicity will be characterized by ADA responses &amp; titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses &lt; 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, ≥ 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the REG5069 ADA assay post first dose when baseline results = negative or missing.</description>
          <population>Anti-Drug Antibody (ADA) Analysis Set: included all treated participants who received any amount of study drug (active or placebo [safety analysis set (SAF)]) and had at least one non-missing anti-REGN5069 antibody result following the first dose of study drug or placebo. ADA analysis set is based on actual treatment received, rather than randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Existing Immunoreactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Boosted Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Emergent Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) and Serious Adverse Events (SAE) were collected from the time of informed consent signature and then at each visit until the end of follow-up visit (week 36) for AEs and until end of study visit (week 52) for SAEs. The study was terminated early at 36 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received matching placebo intravenously every 4 weeks (Q4W)</description>
        </group>
        <group group_id="E2">
          <title>REGN5069 100 mg IV Q4W</title>
          <description>Participants received 100 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
        </group>
        <group group_id="E3">
          <title>REGN5069 1000 mg IV Q4W</title>
          <description>Participants received 1000 milligrams (mg) of REGN5069 intravenously every 4 weeks (Q4W)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="64" subjects_affected="30" subjects_at_risk="88"/>
                <counts group_id="E2" events="36" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E3" events="47" subjects_affected="20" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Administrator</name_or_title>
      <organization>Regeneron Pharmaceuticals, Inc.</organization>
      <phone>844-734-6643</phone>
      <email>clinicaltrials@regeneron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

